Entering text into the input field will update the search result below

Revive Therapeutics says FDA agrees to changes to late-stage study for COVID-19 therapy

Jun. 24, 2022 12:11 PM ETRevive Therapeutics Ltd. (RVVTF) StockBy: Jonathan Block, SA News Editor9 Comments

Concept of a new oral antiviral therapeutic treatment for Covid-19 virus

BackyardProduction/iStock via Getty Images

  • The U.S. FDA has agreed to new primary efficacy endpoints for Revive Therapeutics' (OTCQB:RVVTF) for bucillamine for mild-to-moderate COVID-19.
  • The agency has accepted the company's Data Access Plan that will allow for the unblinding of the pre-dose selection data.
  • The new efficacy endpoints include the rate of sustained clinical resolution of COVID-19 symptoms to indicate the change in the clinical outcome witnessed during the pandemic.
  • Revive previously said that the revised endpoints will provide the FDA with “more meaningful study endpoints."

Recommended For You

About RVVTF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RVVTF--
Revive Therapeutics Ltd.